Get the Stockscreener App
4.56
5.39%
-0.26
Armata Pharmaceuticals Inc stock is traded at $4.56, with a volume of 110.58K.
It is down -5.39% in the last 24 hours and up +16.33% over the past month.
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections in the United States. The company develops its products using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains. The company is also developing and advancing synthetic phage for treating diseases caused by pseudomonas aeruginosa. Armata Pharmaceuticals, Inc. is headquartered in Marina del Rey, California.
See More
Previous Close:
$4.82
Open:
$4.79
24h Volume:
110.58K
Relative Volume:
0.77
Market Cap:
$167.40M
Revenue:
$5.20M
Net Income/Loss:
$-282.61M
P/E Ratio:
-0.5873
EPS:
-7.764
Net Cash Flow:
$-24.47M
1W Performance:
-3.18%
1M Performance:
+16.33%
6M Performance:
-44.05%
1Y Performance:
+80.24%
1-Day Range:
$4.40
$4.9303
1-Week Range:
$3.96
$5.0375
52-Week Range:
$2.40
$16.34
Armata Pharmaceuticals Inc Stock (ARMP) Company Profile
Name
Armata Pharmaceuticals Inc
Sector
Industry
Phone
310-655-2928
Address
4503 Glencoe Avenue, Marina del Rey, CA
Compare ARMP vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARMP
Armata Pharmaceuticals Inc
|
4.56 | 158.22M | 5.20M | -282.61M | -24.47M | -7.764 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Armata Pharmaceuticals Inc Stock (ARMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-19-19 | Initiated | Ladenburg Thalmann | Buy |
Armata Pharmaceuticals Inc Stock (ARMP) Latest News
Armata Pharmaceuticals, Inc. Revenue Breakdown – AMEX:ARMP - TradingView
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Issues Quarterly Earnings Results, Beats Expectations By $0.21 EPS - MarketBeat
Is Armata Pharmaceuticals Inc (ARMP) Facing Challenges After Q2 - GuruFocus
Armata Pharmaceuticals, Inc. 2026: Revenue $2.51M, Net income $74.14M, EPS ($0.27) — 10-Q Summary - TradingView
Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update - PR Newswire
Armata Pharmaceuticals, Inc. Actuals & Estimates (AMEX:ARMP) - TradingView
Armata Pharmaceuticals Inc. (ARMP) Q1 2026 Earnings: Net Loss Wide of Estimates, Cash Burn Remains a Focus - dars.gov.et
ARMP|Armata Pharmaceuticals Inc|Price:5.150|Chg%:+0.490 - TradingKey
Armata Pharmaceuticals Inc - TradingKey
Armata Pharmaceuticals Inc (ARMP) Cash Flow - TradingKey
TradingKey - TradingKey
Armata Pharmaceuticals Inc (ARMP) Shareholder Structure: Major Shareholders & Institutional Holdings - tradingkey.com
ARMP|Armata Pharmaceuticals Inc|Price:4.650|Chg%:-0.570 - TradingKey
Armata Pharmaceuticals Inc (ARMP) Institutional Confidence - TradingKey
Daniel B. Gilmer Net Worth (2026) - GuruFocus
Armata Pharmaceuticals, Inc. (ARMP) stock price, news, quote and history - Yahoo Finance Singapore
Armata Pharmaceuticals, Inc. (ARMP) Stock Price, News, Quote & History - Yahoo! Finance Canada
ARMATA PHARMACEUTICALS INC (ARMP) Stock Chart - ChartMill
Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA) and Armata Pharmaceuticals (ARMP) - The Globe and Mail
Armata Pharmaceuticals (ARMP) Stock Jumps 12.2%: Will It Continue to Soar? - Yahoo! Finance Canada
Armata Pharmaceuticals (ARMP) Advances Towards Phase 3 Study for AP-SA02 - GuruFocus
Armata Pharmaceuticals (ARMP) Advances Superbug Therapy, Stock R - GuruFocus
Armata (ARMP) Names David House as New CFO to Lead Financial Str - GuruFocus
Armata Shares Surge on Progress Toward Late-Stage Trial of Superbug Treatment - Moomoo
Armata submits Phase 3 protocol for antibiotic-resistant drug By Investing.com - Investing.com Nigeria
Armata Pharmaceuticals Names David House as CFO; Advances Staphylococcus Aureus Treatment Candidate - Moomoo
Why Is Armata Pharma Stock Gaining Monday? - Benzinga
H.C. Wainwright Maintains Armata Pharmaceuticals(ARMP.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02 - Morningstar
Armata Advances AP-SA02 Toward Phase 3 Trial Launch - TipRanks
Armata Pharmaceuticals Promotes David House to CFO - TipRanks
Armata submits Phase 3 protocol for antibiotic-resistant drug - Investing.com
Armata Pharmaceuticals: Promising Phage Platform, But Phase 3 Is Everything (NYSE:ARMP) - Seeking Alpha
Form 4 Armata Pharmaceuticals Inc For: 14 July By Investing.com - Investing.com Nigeria
Armata Pharmaceuticals (ARMP) CEO reports tax withholding of 14,041 shares - Stock Titan
Armata Pharmaceuticals, Inc. (ARMP) has received acceptance from the U.S. Food and Drug Administration (FDA) on its initial pediatric study plan for AP-SA02 for the treatment of complicated Staphylococcus aureus bacteremia. - Bitget
Armata receives FDA agreement on pediatric study plan for AP-SA02 - Investing.com UK
Armata Advances AP-SA02 Pediatric Plan With FDA Agreement - TipRanks
Armata Pharmaceuticals (ARMP) Secures FDA Agreement for Pediatri - GuruFocus
Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia - PR Newswire
Armata Pharmaceuticals (ARMP) Trades Slightly Lower as Price Nears Key SupportETF Liquidity - DonanımHaber
Armata Pharmaceuticals, Inc.(NYSEAM:ARMP) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Armata Pharmaceuticals, Inc.(NYSEAM: ARMP) added to Russell 2500 Growth Benchmark - marketscreener.com
Armata Pharmaceuticals, Inc.(NYSEAM: ARMP) added to Russell 2000 Index - marketscreener.com
Armata Pharmaceuticals, Inc.(NYSEAM:ARMP) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Armata Pharmaceuticals, Inc.(NYSEAM: ARMP) added to Russell 3000E Growth Benchmark - marketscreener.com
Armata Pharmaceuticals, Inc.(NYSEAM: ARMP) added to Russell 3000E Index - marketscreener.com
Armata Pharmaceuticals, Inc.(NYSEAM:ARMP) added to Russell Small Cap Completeness Index - marketscreener.com
Enterprise value to EBITDA forward of Armata Pharmaceuticals, Inc. – AMEX:ARMP - TradingView
Armata Pharmaceuticals, Inc.(NYSEAM: ARMP) added to Russell 3000 Growth Benchmark - marketscreener.com
Enterprise value to EBITDA forward of Armata Pharmaceuticals, Inc. – DUS:TG1N - TradingView
Armata Pharmaceuticals Inc Stock (ARMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):